Trial Profile
A Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2011 Planned End Date changed from 1 Nov 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.